Global Fund suspends two malaria grants, terminates TB grant to Mali, on evidence of misappropriation
The Global Fund to Fight AIDS, Tuberculosis and Malaria has suspended funding of two malaria grants in Mali with immediate effect and has terminated a third grant for tuberculosis (TB) after it found evidence of misappropriation and unjustified expenditure. Management of the two suspended grants will be transferred to a new Principal Recipient.
The government of Mali has condemned the embezzlement of funds and is working with the Global Fund to solve problems and ensure that grant activities can resume as soon as possible.
In addition to the Mali grant suspension, the Global Fund is placing grants in five countries on an “Additional Safeguards Policy” list. Grants in countries on this list are subject to closer scrutiny of their grant activities by The Global Fund and have certain restrictions on cash movements. The five countries are Cote d'Ivoire, Djibouti, Mali, Mauritania and Papua New Guinea.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More Features in Pharmaceutical
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze